## DT15 Rec'd PCT/PTO 2 9 JUN 2004 PTO/SB/08A (10-01) ough 10/31/2002. OMB 0651-0031

Approved for ough 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office. J.S. DEPARTMENT OF COMMERCE

Under the Pap	erwork Reduction a	Act of 1995, no perso	ons are required to r	espond to a collection of information unles	s it contains a valid OMB control number.	
Substitute for form 1449A/PTO		Complete if Known				
				Application Number	To be assigned / 5 00	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)			URE	Filing Date	June 29, 2004	
				First Named Inventor	Wu et al.	
				Art Unit	To be assigned	
			**	Examiner Name	To be assigned	
Sheet	1	of	2	Attorney Docket Number	10254.204-US	

U.S PATENT DOCUMENTS						
Examiner Initials	Cite No. 1	Document Number  Number - Kind Code <sup>2</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	
	<del></del>					
		<u> </u>	<u> </u>		<u> </u>	

Foreign Patent Document   Publication Date   Name of Patentee or Applicant of Cited Document   Publication Date   Name of Patentee or Applicant of Cited Document   Name of Cited Document   Name of Cited Document   Name of Cited Document   Name		
GR	sages	т <sup>6</sup>
GR WO 96/23062 A1 08-01-96 Novo Nordisk A/S 69  GR WO 99/48380 A1 09-30-99 Novo Nordisk A/S 69  GR WO 97/20920 A1 06-12-97 Genencor 21 International Inc.  GR WO 97/22691 A1 06-26-97 Primalco Ltd. 48  GR WO 98/28410 A1 07-02-98 Novo Nordisk A/S 53  GR JP 2001-057852 A 03-06-01 Showa Denko KK 10		
GR WO 96/23062 A1 08-01-96 Novo Nordisk A/S 69  GR WO 99/48380 A1 09-30-99 Novo Nordisk A/S 69  GR WO 97/20920 A1 06-12-97 Genencor 21 International Inc.  GR WO 97/22691 A1 06-26-97 Primalco Ltd. 48  GR WO 98/28410 A1 07-02-98 Novo Nordisk A/S 53  GR JP 2001-057852 A 03-06-01 Showa Denko KK 10		
GR WO 99/48380 A1 09-30-99 Novo Nordisk A/S 69  GR WO 97/20920 A1 06-12-97 Genencor International Inc.  GR WO 97/22691 A1 06-26-97 Primalco Ltd. 48  GR WO 98/28410 A1 07-02-98 Novo Nordisk A/S 53  GR JP 2001-057852 A 03-06-01 Showa Denko KK 10		
GR WO 97/20920 A1 06-12-97 Genencor International Inc. GR WO 97/22691 A1 06-26-97 Primalco Ltd. 48 GR WO 98/28410 A1 07-02-98 Novo Nordisk A/S 53 GR JP 2001-057852 A 03-06-01 Showa Denko KK 10		
GR WO 98/28410 A1 07-02-98 Novo Nordisk A/S 53 GR JP 2001-057852 A 03-06-01 Showa Denko KK 10		
GR WO 98/28410 A1 07-02-98 Novo Nordisk A/S 53 GR JP 2001-057852 A 03-06-01 Showa Denko KK 10		
GR JP 2001-057852 A 03-06-01 Showa Denko KK 10		
110.		
		_

Examiner / Ganapathi	ram Raghu/	Date Considered	11/08/2006

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered include copy of this form, with next communication to applicant.

check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner of Patents, Washington, DC 20231.

<sup>&</sup>lt;sup>1</sup> Applicant's unique diation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at <a href="https://www.usplo.gov">www.usplo.gov</a> or MPEP 901.04: <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>6</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>6</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup> Applicant is to place a



Approved for Lugh 10/31/2002. OMB 0551-0031 U.S. Patent and Trademark Office. ...S. DEPARTMENT OF COMMERCE

PTO/SB/08A (10-01)

ation unless it contains a valid OMB control number.

Substitute for	r form 1449A/PTO			Сотрі	ete if Known	
				Application Number	To be assigned / C nn	
INFORMATION DISCLOSURE				Filing Date	June 29, 2664	
STATEMENT BY APPLICANT (use as many sheets as necessary)				First Named Inventor	Wu et al.	
				Art Unit	To be assigned	
			"	Examiner Name	To be assigned	
Sheet	1 2	of	2	Attorney Docket Number	10254.204-US	

Commission	C:t-	OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS  Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title	
Examiner's Initials	Cite No. <sup>1</sup>	of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume- issue number(s), publisher, city and/or country where published	T 2
GR		BHAT ET AL., Thermostable Cellulase and Xylanase from Thermoascus aurantiacus and Their Potential Industrial Applications, American Chemical Society Symposium Series 2000, Chapter 12, 2000, pp. 204-221	1
GR		HONG J. ET AL., Graduate School of Agriculture, Kyoto, 2001	1
GR	*	HONG J. ET AL, Biotechnology Letters, 2003, pp. 657-661, Vol. 25	-
GR		SALOBIR J., Effect of Xylanase alone and in combination with beta-glucanase on energy utilization, nutrient utilization and intestinal viscosity of broilers fed diets based on two wheat samples; Inst. Nutr. Zootech. Dep., Biotech Fax. Univ. Ljubljana, Groblje 3, Slovenia; 1998, pp. 209-213, vol. 62.	(
GR		BEDFORD M.R. ET AL., Process Stability and Methods of Detection of Feed Enzymes in Complet Diets, Archiv fuer Gefluegelkunde, 2001, pp. 377-386	•

/Ganapathiram Raghu/ Date 11/08/2006 Examiner Considered Signature

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>&</sup>lt;sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any
comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark
Office, Washington, OC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner of Patents, Washington, DC 20231.